• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cytology >Indian Academy of Cytologists National Guidelines for Cytopathology Laboratories for Handling Suspected and Positive COVID-19 (SARS-CoV-2) Patient Samples
【24h】

Indian Academy of Cytologists National Guidelines for Cytopathology Laboratories for Handling Suspected and Positive COVID-19 (SARS-CoV-2) Patient Samples

机译：印度细胞学学院患者治疗疑似Covid-19（SARS-COV-2）患者样品的缩细胞病理学实验室

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

COVID-19, caused by the SARS-CoV-2 virus, has been declared a pandemic by the World Health Organization. This scenario has impacted the way we practice cytopathology. Cytology laboratories receive fresh and potentially infectious biological samples including those from the respiratory tract, from COVID-19 positive or suspected patients. Hence, the Indian Academy of Cytologists thought it necessary and fit to bring forth appropriate guidelines starting from transportation, receipt, processing, and reporting of samples in the COVID-19 era. The guidelines are prepared with the aim of safeguarding and protecting the health care personnel including laboratory staff, trainees and cytopathologists by minimizing exposure to COVID-19 so that they remain safe, in order to able to provide a continuous service. We hope that these national guidelines will be implemented across all cytopathology laboratories effectively.
机译：由SARS-COV-2病毒引起的Covid-19已被世界卫生组织宣布大流行。这种情况影响了我们练习细胞病变的方式。细胞学实验室接受来自Covid-19阳性或疑似患者的呼吸道的新鲜和潜在的传染性生物样品。因此，印度细胞学学院认为有必要和适合从Covid-19时代的运输，收据，加工和报告的运输，收据，加工和报告开始的适当指导方针。通过最大限度地降低Covid-19，以旨在保障和保护包括实验室工作人员，学员和细胞病变学家在内的医疗保健人员的准则，以便能够提供连续服务。我们希望这些国家指南将有效地在所有细胞病变实验室中实施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号